ATLAS compared bevacizumab plus erlotinib ( B+E ) with bevacizumab plus placebo ( B+P ) as maintenance therapy after first-line bevacizumab plus chemotherapy ( B+C ) for advanced non-small-cell lung cancer ( NSCLC ) .